Mind Medicine (MindMed) (OTCMKTS:MMEDF) Stock Jumps 1.2% – What’s Next?

Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report) shares rose 1.2% on Friday. The company traded as high as $29.98 and last traded at $29.48. 3,074,414 shares were traded during mid-day trading, a decline of 9% from the average daily volume of 3,376,665 shares. The stock had previously closed at $29.12.

Mind Medicine (MindMed) Trading Up 1.2%

The business’s 50-day simple moving average is $35.52 and its 200-day simple moving average is $30.60.

About Mind Medicine (MindMed)

(Get Free Report)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders. The company’s research focuses on compounds that target serotonin and other neurological pathways, with the goal of creating treatments for conditions with significant unmet medical needs. MindMed’s leading investigational program is MM-120, a formulation of lysergide D-tartrate being studied for generalized anxiety disorder and other potential indications. The company is also developing MM-402, an investigational therapy based on the R-enantiomer of MDMA, for potential use in autism spectrum disorder.

Featured Stories

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.